Thurston Springer Miller Herd & Titak’s NovoCure NVCR Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-343	Closed	-$4.43K	–	1372
2025 Q3	$4.43K	Sell	343 -175	-34%	-$2.34K	0.01%	425
2025 Q2	$9.22K	Buy	518 +1	+0.2%	+$17	﹤0.01%	1161
2025 Q1	$9.21K	Sell	517 -10	-2%	-$227	﹤0.01%	1148
2024 Q4	$15.7K	Buy	527 +2	+0.4%	+$42	﹤0.01%	780
2024 Q3	$8.2K	Buy	525 +16	+3%	+$290	﹤0.01%	1100
2024 Q2	$8.71K	Buy	+509	New	+$8.95K	﹤0.01%	1069

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's NVCR Position: Q4 2025 in Review

Thurston Springer Miller Herd & Titak sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 343 shares — an estimated $4.43K sold.

Thurston Springer Miller Herd & Titak first reported a position in NVCR in Q2 2024 and held it in 6 quarters. The position peaked at $15.7K in Q4 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

Thurston Springer Miller Herd & Titak reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
Thurston Springer Miller Herd & Titak sold 343 NovoCure shares in Q4 2025, an estimated $4.43K.
Thurston Springer Miller Herd & Titak first reported a position in NovoCure in Q2 2024 and held it in 6 quarters.
Thurston Springer Miller Herd & Titak's NovoCure position peaked at $15.7K in Q4 2024.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q4 2025, filed 20 Jan 2026.